An
anti-diabetes herbal drug, jointly developed by two Council of Scientific and
Industrial Research (CSIR) laboratories has been launched in certain parts of
North India. The drug, dubbed BGR-34, has been derived from the medicinal plant
extracts as described in the ancient Ayurveda text.
BGR-34
been jointly developed by National Botanical Research Institute (NBRI) and
Central Institute for Medicinal and Aromatic Plants (CIMAP). For the purpose of
commercialisation, the drug licence has been awarded to Delhi-based Aimil
Pharamaceuticals Pvt. Ltd. In return, Aimil will pay royalty based on drug
sales to CSIR.
The
drug is available in the form of a 500mg pill which needs to be consumed twice
a day by a patient suffering from Type 2 diabetes. BGR-34 was recently approved
by the Indian ministry that looks after traditional Indian medicines, AYUSH.
The Livemint reports that the drug
was tested on a group of 1000 patients from the Indian states of Haryana,
Delhi, Punjab, Karnataka and Himachal Pradesh. The study, which lasted for over
a period of 18 months, found that the escalated blood glucose levels of 67
percent of the patients returned back to normal within three to four days of
drug consumption.
“The
modern diabetes drugs are known for side-effects and toxicity while BGR-34
works by controlling blood sugar and limiting the harmful effects of other
drugs,” said NBRI scientist A.K.S. Rawat in a statement.
The Huffington
Post reports
that the drug has the capability to strengthen the immune system of the patient
and also work as an antioxidant.
Contact the writer at
feedback@ibtimes.com.au, or let us know what you think below.
